MedTrace Logo

Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation

NCT02191670 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2014-07-16

No results posted yet for this study

Summary

Primary: To support the Regulatory Approval process of Metalyse® in Russian Federation. Secondary: To assess the efficacy and safety of single bolus of Metalyse® TNK-tissue plasminogen activator (TNK-tPA, Tenecteplase ) in patients with acute myocardial infarction in usual routine treatment after market launch

Conditions

Interventions

DRUG

METALYSE®

weight-adjusted dosage as single bolus over 5 to 10 seconds

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2006-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02191670 on ClinicalTrials.gov